Use of somatostatin analogue therapy as primary medical treatment of acromegaly

Registry ID

EUCTR2005-004300-36

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Plymouth Hospital NHS Trust, R&D dept

Start date

2006-02-27

Completion date

2010-06-01

Last update

2026-08-16

Conditions

• Acromegaly

Summary

To see whether a twelve month period of primary medical treatment of acromegaly with Somatuline Autogel will produce clinically significant reductions in tumour size from Baseline to Month 12 as assessed using MRI, pre-operatively.

Locations

• , , UK

Related clinical trials

• An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly
• A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
• Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA
• Study of MAR002 in Healthy Men
• Effects of Pasireotide Lar Therapy on Bone Metabolism
• Effects of Therapies in the Acromegaly Disease: Acral Morpho-functional Study

View on source registry